REFERENCES
- Lambrecht RW, Gildemeister OS, Pepe JA et al (1999) Effects of antidepressants and benzodiazepine-type anxiolytic agents on hepatic porphyrin accumulation in primary cultures of chick embryo liver cells. J Pharmacol Exp Ther 291: 1150–5.
- Holroyd S, Seward RL (1999) Psychotropic drugs in acute intermittent porphyria. J Clin Pharmacol Ther 66: 323–5.
- Brosen K (1998) Differences in interactions of SSRIs. J Int Clin Psychopharmacol 13 (5): 45–7.
- Marken AP, Munro S (2000) Selecting selective serotonin reuptake inhibitor: clinically important distinguishing features. Primary Care Companion J Clin Psychiatry 2: 205–10.
- Catterson ML, Preskorn SH (1996) Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. Pharmacol Toxicol 78: 203—8.
- Tishler PV (1999) The effect of therapeutic drugs and other pharmacologic agents on activity of porphobilinogen deaminase, the enzyme that is deficient in intermittent acute porphyria. Life Sci 65: 207–14.
- Moore MR (1980) International review of drugs in acute porphyria. Int J Biochem 12: 1089–97.
- Krummmel SJ, Wesner RB (1986) Exacerbation of acute intermittent porphyria by nortriptyline. Drug Intell Clin Pharm 20: 487—8.
- Vaz FJ, Salcedo MS (1991) Fluoxetine treatment of depressive symptoms in acute intermittent porphyria. J Clin Psychiatry 52: 138.
- Horgan P, Jones H (2003) Olanzapine use in acute porphyria. IntJ Psych Clin Pract 7: 67–69.
- Nemeroff CB, DeVane CL, Pollock BG (1996) Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153 (3): 311–20.
- Sadock BJ, Sadock VA (eds) (2000) Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. Lippincott Williams and Wilkins, PA.